life sciences — Lanton Law Blog

New Trans-Atlantic Drug Pricing Deal: What Supply Chain Stakeholders Must Know

In a major development for the global life-sciences landscape, the United States and the United Kingdom have reached an agreement in principle that reshapes how both countries approach pharmaceutical pricing and cross-border trade.

healthcare, life sciences, pharmaceuticals, PhRMA, prescription drug costs, trade, U.K., United KingdomRon LantonDecember 1, 2025Drug Price, drug pricing, pharmaceuticals, VPAG, U.K., U.S., life sciences, Section 232, 232 investigation

Lanton Law Returns to Moderate Most Favored Nation Panel for Pharmacy Times

Lanton Law retuned to moderate the third and final panel on MFN for Pharmacy Times titled “How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets.”

healthcare, life sciencesRon LantonNovember 25, 2025Most Favored Nation, MFN, drug pricing, healthcare, life sciences

Amazon to Acquire Primary Health Care Provider

Amazon has decided to take another step forward in healthcare by acquiring One Medical.

healthcare, physician, mobile health, telehealthRon LantonJuly 21, 2022healthcare, life sciences, primary care, physicians, antitrust, digital health, mobile health

CMS Proposes Rescinding Most Favored Nation Interim Final Rule

The Centers for Medicare and Medicaid Services (CMS) has released a proposed rule that seeks to rescind the Most Favored Nation Model interim final rule with comment period that appeared in the November 27, 2020 Federal Register. CMS is seeking public comment by October 12, 2021.

CMS, healthcare, HHS, life sciences, Medicare, Medicare Part B, Medicare Part D, pharmaceuticals, pharmacy, prescription drug costs, Most Favored NationRon LantonAugust 10, 2021Most Favored Nation, CMS, Centers for Medicare and Medicaid Services, California Life Sciences, Regeneron Pharmaceuticals, healthcare, life sciences